Photo:
utswmed.org
Mar 5, 2026, 15:51
Samer Al Hadidi: Cytopenias and Infection Risk With BCMA-Directed Bispecific Antibodies
Samer Al Hadidi, Associate Professor at UT Southwestern Medical Center, shared a post on LinkedIn:
“The Overlooked Burden of Cytopenias With BCMA-Directed Bispecific Antibodies
Hematologic toxicity is underappreciated:
- 87% of pts: grade 3-4 lymphopenia
- 55% grade 3-4 neutropenia (65% with teclistamab)
- 74% required dose interruptions
- 54.5% needed G-CSF
This is likely one of the important causes of higher grade infections with those agents.
We need to think about preventive strategies given the high efficacy of those agents.”
Stay updated with Hemostasis Today.
-
Jul 28, 2026, 13:46Manal Rayyan: Efanesoctocog Alfa Shows Excellent Real-World Performance
-
Jul 28, 2026, 13:22Raelene Kambli: Advocating for Safer Blood Access
-
Jul 28, 2026, 13:07Connie Montgomery: Conversations That Change Hemophilia Care
-
Jul 28, 2026, 09:06Payal Desai: Highlights from the NASCC 2026 Sickle Cell Workshop
-
Jul 28, 2026, 08:43Flora Peyvandi։ Acquired Hemophilia A – An Illustrated Review Based on French Guidelines
-
Jul 28, 2026, 08:28Ujjal Didar Singh Sekhon: Exploring SynthoPlate Under P2Y12 Blockade
-
Jul 28, 2026, 08:27Sujeet Katiyar: You Share Patient Data with Your TPA. Where Is the Contract?
-
Jul 28, 2026, 07:50Mihail Celeski: Personalizing Anticoagulant Therapy for Frail Patients With Atrial Fibrillation
-
Jul 28, 2026, 07:36Ifeanyichukwu Ifechidere: What If the Test We’ve Trusted for Decades Has Been Telling Us Half the Story?